Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.84 |
| ▸ | SRC | P12931 | 12/20 | 0.84 |
| ▸ | ABL1 | P00519 | 10/20 | 0.84 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.84 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.84 |
| ▸ | RET | P07949 | 8/20 | 0.84 |
| ▸ | EGFR | P00533 | 7/20 | 0.84 |
| ▸ | HCK | P08631 | 7/20 | 0.84 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.84 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.84 |
| ▸ | MTOR | P42345 | 7/20 | 0.84 |
| ▸ | EPHB4 | P54760 | 7/20 | 0.84 |
| ▸ | PRKDC | P78527 | 7/20 | 0.84 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.84 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.84 |
| ▸ | PLK4 | O00444 | 1/20 | 0.84 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.84 |
| ▸ | CASK | O14936 | 1/20 | 0.84 |
| ▸ | GAK | O14976 | 1/20 | 0.84 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298922 | 0.92 | SRC (1.00) | KDRSRCABL1PIK3CDPIK3CG | |
| SCHEMBL29454801 | 0.92 | SRC (1.00) | KDRSRCABL1PIK3CDPIK3CG | |
| SCHEMBL21082533 | 0.88 | RET (0.79) | KDRSRCABL1PIK3CDPIK3CG | |
| SCHEMBL19464200 | 0.87 | RET (1.00) | KDRSRCABL1PIK3CDPIK3CG | |
| SCHEMBL12422335 | 0.86 | RET (0.81) | KDRSRCABL1PIK3CDPIK3CG | |
| SCHEMBL1296185 | 0.86 | RET (1.00) | KDRSRCABL1PIK3CDPIK3CG | |
| SCHEMBL29388046 | 0.86 | RET (1.00) | KDRSRCABL1PIK3CDPIK3CG | |
| SCHEMBL12422294 | 0.85 | RET (0.74) | KDRSRCABL1PIK3CDPIK3CG | |
| SCHEMBL12422333 | 0.85 | RET (0.73) | KDRSRCABL1PIK3CDPIK3CG | |
| SCHEMBL19476268 | 0.83 | RET (0.80) | KDRSRCABL1PIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976086-B1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3009436-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3009436-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| CN-102124009-A | Kinase inhibitors and methods of use thereof | INTELLIKINE INC | 2011-07-13 | — | — | CN | disclosed |
| EP-2313414-A2 | KINASE INHIBITORS AND METHODS OF USE | Intellikine, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010059593-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS | INTELLIKINE, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010006086-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010006086-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010006072-A2 | MTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010006072-A2 | MTOR MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | KDR 698/4885SRC 54/4885ABL1 73/4885 |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | AURKC, MTOR, AURKA | KDR 2868/4885SRC 1374/4885ABL1 796/4885 |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | KDR 3481/4885SRC 825/4885ABL1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.